medigraphic.com
ISSN 1729-519X (Print)

2021, Number 1

<< Back Next >>

Revista Habanera de Ciencias Médicas 2021; 20 (1)

Efficacy of mobilization of stem cells in patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Lambert GM, Mesa BY, Ferrer GY, Moncada RI

Language: Spanish
References: 29
Page: 1-15
PDF size: 782.13 Kb.


ABSTRACT

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune demyelinating disease. Conventional treatment is based on immunomodulation and immunosuppression. The use of stem cells is a novel therapy in autoimmune disorders, so it is included as therapy.
Objective: To determine the efficacy of mobilization of stem cells by applying granulocyte colony-stimulating factor (G-CSF) in patients with CIDP who have followed other lines of treatment.
Material and Methods: A randomized, double-blind study was carried out on a cohort of 45 patients with CIDP. G-CSF was administered to 25 patients and 20 of them continued with the usual treatment. These patients were previously treated with other therapeutic variants for more than three years without satisfactory response.
Results: There was a prevalence of men (64.4 %), Diabetes Mellitus had a greater association, and the most used medications were steroids. Clinical symptoms and signs improved significantly after treatment. TCSS scores significantly decreased at one and three months after treatment, but this decrease was not maintained at the end of the study. The conduction velocity and action potential of sensory and motor nerves improved considerably after treatment.
Conclusions: The effectiveness of the use of G-CSF shows an improvement of clinical symptoms. The results of neurophysiological studies have a better course than other therapeutic variants during the first months, with good safety and tolerability, so it can be included in the conventional therapy for the CIDP.


REFERENCES

  1. Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol [Internet]. 2009 Jan [Citado 04/04/2020];155:1-15. Disponible en: Disponible en: http://www.doi.org.10.1111/j.1365-2249.2008.03834.x

  2. Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry [Internet]. 2015 Sep [Citado 04/04/2020];86(9):973-85. Disponible en: Disponible en: http://www.doi.org.10.1136/jnnp-2014-309697

  3. Wang L, Yuan XZ, Zhao XM. Incomplete intestinal obstruction as an initial and persistent presentation in chronic inflammatory demyelinating polyneuropathy: A case report. Medicine (Baltimore) [Internet]. 2018 Dec [Citado 04/04/2020];97(49):e13538. Disponible en: Disponible en: http://www.doi.org.10.1097/MD.0000000000013538

  4. Tsuzaki Koji, Someda Hitoshi, Inoue Manabu, Tachibana Naoko, Hamano Toshiaki. Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. Muscle Nerve [Internet]. 2018 Nov [Citado 04/04/2020];58(5):E34-6. Disponible en: Disponible en: http://www.doi.org.10.1002/mus.26182

  5. Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplantation [Internet]. 2015 [Citado 04/04/2020];50(2):173-80. Disponible en: Disponible en: http://www.doi.org.10.1038/bmt.2014.251

  6. Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta [Internet]. 2015 Apr [Citado 04/04/2020];1852(4):658-66. Disponible en: Disponible en: http://www.doi.org.10.1016/j.bbadis.2014.06.013

  7. Hernández P, Dorticós E. Medicina regenerativa. Células madre embrionarias y adultas. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2009 [Citado 04/04/2020];25(1):[Aprox. 2p.]. Disponible en: Disponible en: http://bvs.sld.cu/revistas/hih/vol25_1_09/hih02109.htm

  8. Cortina L, Hernández P, López De Roux MR, Artaza HM, Dorticós E, Macías C, et al. Aislamiento de células mononucleares de sangre periférica para trasplante de células madre: método simplificado. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2008 [Citado 04/04/2020];24(3):[Aprox. 2p.]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-2892008000300004&lng=es&nrm=iso&tlng=es

  9. León L, Díaz AJ, Hernández NM, Meliáns S. Obtención y procesamiento de células madre autólogas a partir de sangre periférica en diferentes enfermedades. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2009 [Citado 04/04/2020];25(3):[Aprox. 2p.]. Disponible en: Disponible en: http://bvs.sld.cu/revistas/hih/vol25_04_09/hih02409.htm

  10. Cornblath DR, Asbury AK , Albers JW. Ad hoc subcommittee of AAN AIDS task force: Research criteria for diagnosis of chronic inflammatory demyelinating polineuropathy. Neurology. 1991; 41: 617-8.

  11. Bril V, Tomioka S, Buchanan RA, Perkins BA. Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. Diabet Med [Internet]. 2009 Mar [Citado 04/04/2020];6(3):240-6. Disponible en: Disponible en: http://www.doi.org.10.1111/j.1464-5491.2009.02667.x

  12. Bril V, Tomioka S, Buchanan RA, Perkins BA. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med [Internet]. 2009 Mar [Citado 04/04/2020];26(3):240-6. Disponible en: Disponible en: http://www.doi.org.10.1111/j.1464-5491.2009.02667.x

  13. Hernández Hernández A. Evolución electrofisiológica de un grupo de pacientes con Polineuropatía Desmielinizante Inflamatoria Crónica primaria y secundaria. Rev Cuba Invest Bioméd [Internet]. 2008 Mar [Citado 04/04/2020];27(1):[Aprox. 2p.]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002008000100007&lng=es

  14. Straver DC, Van den Berg LH, Franssen H. Activity-dependent conduction block in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci [Internet]. 2011 Jan [Citado 04/04/2020];300(1-2):33-8. Disponible en: Disponible en: http://www.doi.org.10.1016/j.jns.2010.10.008

  15. Van Lieverloo GGA, Peric S, Doneddu PE, Gallia F, Nikolic A, Wieske L, et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicenter study, comparing efficacy and safety of daily prednisolone, pulse dexamethasone, and pulsed intravenous methylprednisolone. J Neurol [Internet]. 2018 [Citado 04/04/2020];265(9):2052-9. Disponible en: Disponible en: http://www.doi.org.10.1007/s00415-018-8948-y

  16. Eftimov F, Vermeulen M, Van Doorn PA. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology [Internet]. 2012 [Citado 04/04/2020];78(14):1079-84. Disponible en: Disponible en: http://pascalfrancis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25944238

  17. Markvardsen LH, Sindrup SH, Christiansen I, Oslen NK, Jakobsen J, Andersen H. Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin as first-line therapy in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol [Internet]. 2017 Feb [Citado 04/04/2020];24(2):412-8. Disponible en: Disponible en: http://www.doi.org.10.1111/ene.13218

  18. Van Schaik IN, Bril V, Van Geloven N, Peter Hartung H, Lewis RA, Sobue G, et al. PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind,placebo-controlled, phase 3 trial. Lancet Neurol [Internet]. 2018 Jan [Citado 04/04/2020];17(1):35-46. Disponible en: Disponible en: http://dx.doi.org/10.1016/S1474-4422(17)30378-2

  19. Hahn AF, Bolton CF, Pillay N. Plasma-exchangetherapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled cross-over study. Brain [Internet]. 1996 [Citado 04/04/2020];119(4):1055-66. Disponible en: Disponible en: http://www.doi.org.10.1093/brain/119.4.1055

  20. Takeuchi A, Shirai S, Horiuchi K. Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels. Rinsho Shinkeigaku. 2012;52(3):172-7.

  21. Arai M. A case of intravenous immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy of pure motor form responsive to mycophenolatemofetil therapy. Rinsho Shinkeigaku [Internet]. 2016 Oct [Citado 04/04/2020];56(10):698-701. Disponible en: Disponible en: http://www.doi.org.10.5692/clinicalneurol.cn-000904

  22. Pitarokoili K, Yoon MS, Kröger I, Reinacher Schick A, Gold R, Schneider Gold C. Severe refractory CIDP: a case series of 10 patients treated with bortezomib. Journal of Neurology [Internet]. 2017 Sep [Citado 04/04/2020];264(9):2010-20. Disponible en: Disponible en: http://www.doi.org.10.1007/s00415-017-8599-4

  23. Naito H, Takeda I, Segawa A. A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon a-2a in a patient with chronic hepatitis B virus infection. Rinsho Shinkeigaku [Internet]. 2016 [Citado 04/04/2020];56(10):672-7. Disponible en: Disponible en: https://doi.org.10.5692/clinicalneurol.cn-000888

  24. Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X. Progress in Hematopoietic Stem Cell Transplantation for CIDP. Int J Med Sci [Internet]. 2020 Jan [Citado 04/04/2020];17(2):234-41. Disponible en: Disponible en: http://www.doi.org.10.7150/ijms.38363. eCollection 2020

  25. Mao H, Wei W, Fu XL, Dong JJ, Lyu XY, Jia T, et al. Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy. Chin Med J (Engl) [Internet]. 2019 Jan 5 [Citado 04/04/2020];132(1):11-6. Disponible en: Disponible en: http://www.doi.org.10.1097/CM9.0000000000000009

  26. Nobuta H, Katagi M, Kume S, Terashima T, Araki SI, Maegawa H, et al. A role for bone marrow-derived cells in diabetic nephropathy. FASEB J [Internet]. 2019 Mar [Citado 04/04/2020];33(3):4067-76. Disponible en: Disponible en: http://www.doi.org.10.1096/fj.201801825R

  27. Kotas R, Vokurka S, Bozovsky T, Matousek V, Peterka M. Treatment of CIDP with autologous stem cells transplantation - A case report. Clinical Neurophysiology [Internet]. 2016 Mar [Citado 04/04/2020];127(3):e18-e32. Disponible en: Disponible en: http://www.doi.org.10.1016/j.clinph.2015.11.213

  28. Scheibe F, Alexander T, Prüss H, Wengert O, Harms L, Angstwurm K, et al. Devastating humoral CIDP variant remitted by autologous stem cell transplantation. Eur J Neurol [Internet]. 2016 Feb [Citado 04/04/2020];23(3):e12-4. Disponible en: Disponible en: http://www.doi.org.10.1111/ene.12896

  29. Tichelli A, Rovo A, Passweg J, Schwarze CP, Van Lint MT, Arat M. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009;2(5):583-601.




2020     |     www.medigraphic.com